BID Monoclonal Antibody

This gene encodes a death agonist that heterodimerizes with either agonist BAX or antagonist BCL2. The encoded protein is a member of the BCL-2 family of cell death regulators. It is a mediator of mitochondrial damage induced by caspase-8 (CASP8); CASP8 cleaves this encoded protein, and the COOH-terminal part translocates to mitochondria where it triggers cytochrome c release. Multiple alternatively spliced transcript variants have been found, but the full-length nature of some variants has not been defined.

Introducing the BID Monoclonal Antibody, a cutting-edge biotechnological innovation designed to revolutionize the field of immunology. This meticulously engineered antibody is meticulously crafted to specifically target and bind to the BID protein, a crucial regulator of apoptosis.

With its exceptional specificity and high affinity, the BID Monoclonal Antibody offers unparalleled accuracy and reliability in detecting and quantifying BID protein levels. Its advanced monoclonal technology ensures consistent and reproducible results, making it an indispensable tool for researchers and clinicians alike.

The BID Monoclonal Antibody boasts exceptional versatility, enabling its utilization in a wide range of applications, including Western blotting, immunoprecipitation, immunofluorescence, and flow cytometry. Its robust performance guarantees precise and efficient detection, facilitating comprehensive investigations into the intricate mechanisms of apoptosis.

Furthermore, this antibody is manufactured under stringent quality control measures, ensuring its purity, stability, and consistency. Its formulation is optimized to minimize non-specific binding, thereby enhancing the accuracy and specificity of experimental outcomes.

The BID Monoclonal Antibody is supplied in a convenient and user-friendly format, allowing for seamless integration into laboratory workflows. Its long shelf life and exceptional storage stability ensure prolonged usability, eliminating concerns of product degradation.

In summary, the BID Monoclonal Antibody represents a breakthrough in immunological research, offering researchers and clinicians an invaluable tool to unravel the complexities of apoptosis. With its exceptional specificity, versatility, and reliability, this antibody is poised to redefine the boundaries of scientific exploration in the field of immunology.